Effect of different statins and EZETIMIBE/SIMVASTATIN on cardiovascular disease in patients with chronic kidney disease

Effect of different statins and EZETIMIBE/SIMVASTATIN on cardiovascular disease in patients with chronic kidney disease

Objective To explore the effect of different statins and EZETIMIBE/SIMVASTATIN on cardiovascular disease in patients with chronic kidney disease(CKD). Methods This study was a prospective study design and selected 503 cases of 3-5 phase CKD patients. The subjects were divided into simvastatin group,...

Full description

Saved in:

Bibliographic Details
Main Authors:	ZHANG Xue-qing, Yiming·Muyesaier, Abualiti·Alimire, LU Chen
Format:	Article
Language:	zho
Published:	Editorial Department of Journal of Clinical Nephrology 2018-01-01
Series:	Linchuang shenzangbing zazhi
Subjects:	Chronic kidney disease Statins EZETIMIBE/SIMVASTATIN Cardiovascular disease
Online Access:	http://www.lcszb.com/thesisDetails?columnId=57915013&Fpath=home&index=0
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

ESCADRA: a randomised study. Part I: lipid-lowering effectiveness, safety and tolerability of ezetimibe, initial doses of original statins, and the combination of ezetimibe with initial doses of statins in patients with coronary heart disease and hyperlipidemia
by: M. Yu. Zubareva, et al.
Published: (2010-12-01)

Combined hypolipidemic therapy in patients who failed to achieve target values of the lipidogram. Possibilities of ezetimibe
by: N. V. Fedorova, et al.
Published: (2021-06-01)

The clinical effectiveness and safety of low/moderate-intensity statins & ezetimibe combination therapy vs. high-intensity statin monotherapy: a systematic review and meta-analysis
by: Pishoy Sydhom, et al.
Published: (2024-11-01)

Combination of statin and ezetimibe in the post-infarction period
by: Valentin E. Oleynikov, et al.
Published: (2024-12-01)

Simultaneous inhibition of cholesterol absorption and synthesis in combined therapy with ezetimibe and simvastatin
by: D. M. Aronov
Published: (2005-08-01)

Addition of Bempedoic Acid to Statin–Ezetimibe versus Statin Titration in Patients with High Cardiovascular Risk: A Single-Centre Prospective Study
by: Giuseppe Marazzi, et al.
Published: (2024-09-01)

Ezetimibe potential in cardiology practice
by: A. A. Lyakishev, et al.
Published: (1970-01-01)

Clinical effects of statins: focusing on simvastatin
by: D. M. Aronov, et al.
Published: (2009-04-01)

EFFECT OF SIMVASTATIN ON MARKERS OF CARDIOVASCULAR RISK
by: N. V. Perova, et al.
Published: (2016-01-01)

Clinical Outcomes of Ezetimibe Plus Statins in Patients With Lower Extremity Artery Disease
by: Yoshihiro Iwasaki, MD, PhD, et al.
Published: (2025-09-01)

Study Design and Protocol for a Randomized Controlled Trial to Assess Long-Term Efficacy and Safety of a Triple Combination of Ezetimibe, Fenofibrate, and Moderate-Intensity Statin in Patients with Type 2 Diabetes and Modifiable Cardiovascular Risk Factors (ENSEMBLE)
by: Nam Hoon Kim, et al.
Published: (2024-10-01)

Triple Non-Statin Therapy with Ezetimibe, Inclisiran, and Bempedoic Acid in Patients with Genetically Confirmed Statin-Induced Rhabdomyolysis: A Dual Case Report
by: Jozef Dodulík, et al.
Published: (2025-05-01)

NEWS OF EVIDENCE-BASED MEDICINE: RESULTS OF THE IMPROVE-IT TRIAL AND THEIR IMPLICATIONS FOR CLINICAL PRACTICE
by: S. Yu. Martsevich
Published: (2015-09-01)

Randomised study of ezetimibe, start doses of original statins, and their combination in patients with coronary heart disease and hyperlipidemia Part 2. Therapy effects on the levels of C-reactive protein and proinflammatory cytokines
by: A. V. Susekov, et al.
Published: (2011-12-01)

Comparison of rosuvastatin 10 mg plus ezetimibe versus rosuvastatin 20 mg in atherosclerotic cardiovascular disease and type 2 diabetes
by: Hyo-In Choi, et al.
Published: (2025-05-01)

Efficacy and safety of inclisiran versus PCSK9 inhibitor versus statin plus ezetimibe therapy in hyperlipidemia: a systematic review and network meta-analysis
by: Shengxuan Zhang, et al.
Published: (2024-11-01)

STATINS AND RISK OF INFECTIOUS DISEASES
by: O. M. Drapkina, et al.
Published: (2015-09-01)

The anti-inflammatory properties of simvastatin can benefit statin-naïve rheumatoid arthritis patients with associated risks for cardiovascular disease
by: A.O. Komolafe, et al.
Published: (2015-02-01)

СLINICAL EFFICIENCY OF STATINS IN RHEUMATOID ARTHRITIS: A PILOT STUDY
by: I. V. Shirinsky, et al.
Published: (2014-07-01)

UP TO DATE STATINS IN PRIMARY AND SECONDARY PREVENTION OF CARDIOVASCULAR DISEASES
by: N. F. Puchin'yan, et al.
Published: (2015-12-01)

Cost-effectiveness analysis of using atorvastatin, simvastatin, ezetimibe, alirocumab, evolocumab, inclisiran in adults with very high cardiovascular risk under the preferential drug provision program
by: T. O. Bessonova, et al.
Published: (2023-04-01)

New experimental possibilities for statin myopathy diagnosing
by: E. V. Vinogradova, et al.
Published: (2021-07-01)

Biochemical, structural and clinical analysis of statins’ pleiotropic effects
by: A. N. Britov, et al.
Published: (2009-10-01)

NEW OPPORTUNITIES FOR PREVENTIVE THERAPY WITH STATINS DURING CHD PATIENTS’ REHABILITATION, WITH CLINICAL SIGNS OF MODERATE CHF: EFFECTIVENESS OF ROSUVASTATIN AND EZETIMIBE
by: N. I. Tarasov, et al.
Published: (2016-06-01)

The effect of use simvastatin at treatment of ischemic heart disease patients of senile age
by: A. L. Pirogov, et al.
Published: (2007-10-01)

Species Differences in Ezetimibe Glucuronidation
by: Shalom Emmanuel, et al.
Published: (2024-10-01)

The Effect of Local Simvastatin on Alveolar Bone Regeneration, Pain, and Swelling After Tooth Extraction: a Systematic Review
by: Ariel Aminov, et al.
Published: (2025-06-01)

Statin effects on the lipidome: Predicting statin usage and implications for cardiovascular risk prediction
by: Changyu Yi, et al.
Published: (2025-05-01)

Effect of Simvastatin on the spectrum of blood plasma fat acids change in the patients with ischemia heart disease
by: V. V. Novitsky, et al.
Published: (2008-09-01)

Prediction of basal glycaemia dynamics during treatment with 6-month lipid-lowering therapy in patients at high risk of cardiovascular disease
by: Olga A. Koshelskaya, et al.
Published: (2017-12-01)

Antioxidant effects of simvastatin in patients with coronary heart disease and dyslipidemia
by: N. E. Artamoshina, et al.
Published: (2012-12-01)

COURAGE study results: disappointing or encouraging?
by: D. M. Aronov, et al.
Published: (1970-01-01)

Lipid profile and safety of rosuvastatin monotherapy versus rosuvastatin plus ezetimibe in high risk coronary artery disease: a systematic review and meta-analysis of randomized controlled trials
by: Arga Setyo Adji, et al.
Published: (2025-06-01)

THE PROBLEM OF STATIN USE IN PATIENTS WITH CARDIOVASCULAR DISEASES AND CONCOMITANT LIVER DISEASES. WHAT DO PRACTICING PHYSICIANS THINK ABOUT IT?
by: S. Yu. Martsevich, et al.
Published: (2015-09-01)

The impact of the nocebo effect on discontinuation of statin therapy due to myopathy in patients with cardiovascular disease – a review
by: Jakub Stanek, et al.
Published: (2024-11-01)

Advances in the role of statins in acute kidney disease
by: Hu Quan, et al.
Published: (2021-01-01)

THE PROBLEM OF STATIN USE IN PATIENTS WITH CARDIOVASCULAR DISEASES AND CONCOMITANT LIVER DISEASES. WHAT PREVENTS OVERCOMING STATINOPHOBIA?
by: S. N. Bel'diev
Published: (2016-06-01)

Change in the fatty acids spectrum of erythrocyte in patients with chronic form of coronary heart disease in treatment by Simvastatin
by: V. V. Novitsky, et al.
Published: (2012-02-01)

The influence of Simvastatin and Korargin on the clinical course of coronary heart disease, body weight and distribution of adipose tissue in patients with type 2 diabetes mellitus.
by: E. A. Pogrebniak
Published: (2013-06-01)

Population Pharmacokinetics and Pharmacodynamics with Enterohepatic Recirculation of Co-Medication of Rosuvastatin and Ezetimibe
by: An H, et al.
Published: (2025-06-01)